Download PDF
Semin Thromb Hemost 2019; 45(08): 802-809
DOI: 10.1055/s-0039-1698829
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Platelets as Central Actors in Thrombosis—Reprising an Old Role and Defining a New Character

Hannah Stevens
1   Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, Australia
2   Department of Medicine, Monash University, Melbourne, Australia
3   Department of Clinical Haematology, Alfred Hospital, Melbourne, Australia
,
James D. McFadyen
1   Atherothrombosis and Vascular Biology Program, Baker Heart and Diabetes Institute, Melbourne, Australia
2   Department of Medicine, Monash University, Melbourne, Australia
3   Department of Clinical Haematology, Alfred Hospital, Melbourne, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
17 October 2019 (online)

    Permissions and Reprints

Abstract

Platelets have long been considered simple anucleate cells that rapidly adhere and aggregate at sites of vascular injury. However, recent in vivo experimental data have shed new light on the platelet response to vascular injury. These data have unexpectedly revealed that platelet thrombus formation is a highly dynamic process and yields a platelet thrombus with a distinct hierarchical structure composed of a “core” of highly activated platelets and a “shell” of platelets in a low activation state. This has given rise to the concept that therapeutic targeting of the propagating thrombus shell may hold promise as a means to target thrombosis while sparing hemostasis. While platelets have been historically considered central to arterial thrombosis, they have been traditionally viewed as minor contributors to the formation of venous thrombosis. However, this concept has recently been challenged with the emergence of a large body of evidence highlighting the important proinflammatory function of platelets. The proinflammatory function of platelets is afforded by their ability to induce neutrophil extracellular trap formation, enhance leucocyte recruitment, and secrete granular contents such as high mobility group protein B1 and polyphosphate. These proinflammatory processes trigger coagulation, via the intrinsic pathway, and are central to the formation of venous thrombosis, a condition now appreciated to be a form of sterile inflammation. These data now place platelets at the center stage in orchestrating the thromboinflammatory response underpinning venous thrombosis and have provided new hope that novel platelet-targeted therapeutics may represent a safe and effective approach to prevent venous thrombosis.

Keywords

arterial thrombosis - venous thrombosis - platelets - antithrombotic - bleeding
 

  • References

  • 1 Brewer DB. Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet. Br J Haematol 2006; 133 (03) 251-258
    CrossrefPubMedGoogle Scholar
  • 2 Brass LF, Diamond SL, Stalker TJ. Platelets and hemostasis: a new perspective on an old subject. Blood Adv 2016; 1 (01) 5-9
    CrossrefPubMedGoogle Scholar
  • 3 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8 (11) 1227-1234
    CrossrefPubMedGoogle Scholar
  • 4 Benjamin EJ, Muntner P, Alonso A. , et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: a report from the American Heart Association. Circulation 2019; 139 (10) e56-e528
    PubMedGoogle Scholar
  • 5 McFadyen JD, Jackson SP. Differentiating haemostasis from thrombosis for therapeutic benefit. Thromb Haemost 2013; 110 (05) 859-867
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Semple JW, Italiano Jr JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11 (04) 264-274
    CrossrefPubMedGoogle Scholar
  • 7 McFadyen JD, Kaplan ZS. Platelets are not just for clots. Transfus Med Rev 2015; 29 (02) 110-119
    CrossrefPubMedGoogle Scholar
  • 8 von Brühl ML, Stark K, Steinhart A. , et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209 (04) 819-835
    CrossrefPubMedGoogle Scholar
  • 9 Zahn F. Untersuchungen uber Thrombose: Bildung der Thromben. Virchows Arch A Pathol Anat Histol 1875; 61: 81-124
    PubMedGoogle Scholar
  • 10 Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol 1991; 68 (07) 28B-35B
    CrossrefPubMedGoogle Scholar
  • 11 Stalker TJ, Traxler EA, Wu J. , et al. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood 2013; 121 (10) 1875-1885
    CrossrefPubMedGoogle Scholar
  • 12 Nesbitt WS, Westein E, Tovar-Lopez FJ. , et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009; 15 (06) 665-673
    CrossrefPubMedGoogle Scholar
  • 13 Welsh JD, Stalker TJ, Voronov R. , et al. A systems approach to hemostasis: 1. The interdependence of thrombus architecture and agonist movements in the gaps between platelets. Blood 2014; 124 (11) 1808-1815
    PubMedGoogle Scholar
  • 14 Stalker TJ, Welsh JD, Tomaiuolo M. , et al. A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. Blood 2014; 124 (11) 1824-1831
    PubMedGoogle Scholar
  • 15 McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol 2018; 15 (03) 181-191
    CrossrefPubMedGoogle Scholar
  • 16 Ju L, McFadyen JD, Al-Daher S. , et al. Compression force sensing regulates integrin αIIbβ3 adhesive function on diabetic platelets. Nat Commun 2018; 9 (01) 1087
    CrossrefPubMedGoogle Scholar
  • 17 Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109 (12) 5087-5095
    CrossrefPubMedGoogle Scholar
  • 18 Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol 2008; 143 (02) 180-190
    CrossrefPubMedGoogle Scholar
  • 19 Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol 1974; 27 (07) 517-528
    CrossrefPubMedGoogle Scholar
  • 20 Budnik I, Brill A. Immune factors in deep vein thrombosis initiation. Trends Immunol 2018; 39 (08) 610-623
    CrossrefPubMedGoogle Scholar
  • 21 Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 2011; 118 (26) 6743-6751
    CrossrefPubMedGoogle Scholar
  • 22 Brill A, Fuchs TA, Chauhan AK. , et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011; 117 (04) 1400-1407
    CrossrefPubMedGoogle Scholar
  • 23 Fuchs TA, Brill A, Duerschmied D. , et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010; 107 (36) 15880-15885
    CrossrefPubMedGoogle Scholar
  • 24 Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012; 32 (08) 1777-1783
    CrossrefPubMedGoogle Scholar
  • 25 Brinkmann V, Reichard U, Goosmann C. , et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303 (5663): 1532-1535
    CrossrefPubMedGoogle Scholar
  • 26 Massberg S, Grahl L, von Bruehl ML. , et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16 (08) 887-896
    CrossrefPubMedGoogle Scholar
  • 27 Tsai AW, Cushman M, Rosamond WD. , et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113 (08) 636-642
    CrossrefPubMedGoogle Scholar
  • 28 Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345 (8943): 152-155
    CrossrefPubMedGoogle Scholar
  • 29 Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood 2007; 109 (06) 2424-2429
    CrossrefPubMedGoogle Scholar
  • 30 Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol 2012; 3: 283
    PubMedGoogle Scholar
  • 31 Uhrin P, Zaujec J, Breuss JM. , et al. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood 2010; 115 (19) 3997-4005
    CrossrefPubMedGoogle Scholar
  • 32 Suzuki-Inoue K, Osada M, Ozaki Y. Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood. J Thromb Haemost 2017; 15 (02) 219-229
    CrossrefPubMedGoogle Scholar
  • 33 Payne H, Ponomaryov T, Watson SP, Brill A. Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis. Blood 2017; 129 (14) 2013-2020
    CrossrefPubMedGoogle Scholar
  • 34 Simon DI, Chen Z, Xu H. , et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192 (02) 193-204
    CrossrefPubMedGoogle Scholar
  • 35 Wang Y, Gao H, Shi C. , et al. Corrigendum: leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIbα. Nat Commun 2017; 8: 16124
    CrossrefPubMedGoogle Scholar
  • 36 André P, Hartwell D, Hrachovinová I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A 2000; 97 (25) 13835-13840
    CrossrefPubMedGoogle Scholar
  • 37 Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 2005; 3 (08) 1590-1596
    CrossrefPubMedGoogle Scholar
  • 38 Wolberg AS, Rosendaal FR, Weitz JI. , et al. Venous thrombosis. Nat Rev Dis Primers 2015; 1: 15006
    CrossrefPubMedGoogle Scholar
  • 39 Palabrica T, Lobb R, Furie BC. , et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359 (6398): 848-851
    CrossrefPubMedGoogle Scholar
  • 40 Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004; 10 (04) 171-178
    CrossrefPubMedGoogle Scholar
  • 41 Celi A, Pellegrini G, Lorenzet R. , et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A 1994; 91 (19) 8767-8771
    CrossrefPubMedGoogle Scholar
  • 42 Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 2018; 18 (02) 134-147
    CrossrefPubMedGoogle Scholar
  • 43 Clark SR, Ma AC, Tavener SA. , et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13 (04) 463-469
    CrossrefPubMedGoogle Scholar
  • 44 Etulain J, Martinod K, Wong SL, Cifuni SM, Schattner M, Wagner DD. P-selectin promotes neutrophil extracellular trap formation in mice. Blood 2015; 126 (02) 242-246
    PubMedGoogle Scholar
  • 45 Stark K, Philippi V, Stockhausen S. , et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood 2016; 128 (20) 2435-2449
    PubMedGoogle Scholar
  • 46 Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5 (04) 331-342
    CrossrefPubMedGoogle Scholar
  • 47 Vogel S, Bodenstein R, Chen Q. , et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest 2015; 125 (12) 4638-4654
    CrossrefPubMedGoogle Scholar
  • 48 Semeraro F, Ammollo CT, Morrissey JH. , et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011; 118 (07) 1952-1961
    PubMedGoogle Scholar
  • 49 Gould TJ, Vu TT, Swystun LL. , et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol 2014; 34 (09) 1977-1984
    CrossrefPubMedGoogle Scholar
  • 50 Kornberg A, Rao NN, Ault-Riché D. Inorganic polyphosphate: a molecule of many functions. Annu Rev Biochem 1999; 68: 89-125
    CrossrefPubMedGoogle Scholar
  • 51 Rao NN, Gómez-García MR, Kornberg A. Inorganic polyphosphate: essential for growth and survival. Annu Rev Biochem 2009; 78: 605-647
    CrossrefPubMedGoogle Scholar
  • 52 Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004; 279 (43) 44250-44257
    CrossrefPubMedGoogle Scholar
  • 53 Morrissey JH, Smith SA. Polyphosphate as modulator of hemostasis, thrombosis, and inflammation. J Thromb Haemost 2015; 13 (Suppl. 01) S92-S97
    CrossrefPubMedGoogle Scholar
  • 54 Müller F, Mutch NJ, Schenk WA. , et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139 (06) 1143-1156
    CrossrefPubMedGoogle Scholar
  • 55 Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A 2006; 103 (04) 903-908
    CrossrefPubMedGoogle Scholar
  • 56 Becattini C, Agnelli G, Schenone A. , et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366 (21) 1959-1967
    CrossrefPubMedGoogle Scholar
  • 57 Brighton TA, Eikelboom JW, Mann K. , et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367 (21) 1979-1987
    CrossrefPubMedGoogle Scholar
  • 58 Weitz JI, Lensing AWA, Prins MH. , et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
    CrossrefPubMedGoogle Scholar
  • 59 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 60 Stevens H, Tran H. Update on diagnosis and anticoagulant therapy for venous thromboembolism. Intern Med J 2018; 48 (10) 1175-1184
    CrossrefPubMedGoogle Scholar
  • 61 Anderson DR, Dunbar M, Murnaghan J. , et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med 2018; 378 (08) 699-707
    CrossrefPubMedGoogle Scholar
  • 62 Schwarz M, Meade G, Stoll P. , et al. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 2006; 99 (01) 25-33
    CrossrefPubMedGoogle Scholar
  • 63 Stoll P, Bassler N, Hagemeyer CE. , et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol 2007; 27 (05) 1206-1212
    CrossrefPubMedGoogle Scholar
  • 64 Hanjaya-Putra D, Haller C, Wang X. , et al. Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis. JCI Insight 2018; 3 (15) 99329
    CrossrefPubMedGoogle Scholar
  • 65 Travers RJ, Shenoi RA, Kalathottukaren MT, Kizhakkedathu JN, Morrissey JH. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 2014; 124 (22) 3183-3190
    PubMedGoogle Scholar
  • 66 Smith SA, Choi SH, Collins JN, Travers RJ, Cooley BC, Morrissey JH. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 2012; 120 (26) 5103-5110
    PubMedGoogle Scholar
  • 67 Labberton L, Kenne E, Long AT. , et al. Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection. Nat Commun 2016; 7: 12616
    Google Scholar
  • 68 Scully M, Minkue Mi Edou J, Callewaert F. Caplacizumab for acquired thrombotic thrombocytopenic purpura. Reply. N Engl J Med 2019; 380 (18) e32
    CrossrefPubMedGoogle Scholar
  • 69 Plow EF, Wang Y, Simon DI. The search for new antithrombotic mechanisms and therapies that may spare hemostasis. Blood 2018; 131 (17) 1899-1902
    CrossrefPubMedGoogle Scholar